Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 4/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269946 | 0.91 | PTGDR2 (0.40) | PTGDR2PTGDRPPARGPPARDPPARA | |
| SCHEMBL1269518 | 0.88 | PTGDR (0.39) | PTGDR2PTGDRHSD11B1ALDH1A1 | |
| SCHEMBL1268565 | 0.88 | PTGDR2 (0.43) | PTGDR2PTGDRRORCCMA1PPARG | |
| SCHEMBL1269948 | 0.87 | PTGDR (0.38) | PTGDR2PTGDRRORCPPARGPPARD | |
| SCHEMBL1268968 | 0.86 | PPARG (0.37) | PTGDR2PTGDRPPARGPPARDPPARA | |
| SCHEMBL1268967 | 0.85 | PTGDR (0.36) | PTGDR2PTGDRHSD11B1PIK3C3CCR4 | |
| SCHEMBL1269493 | 0.85 | HTT (0.38) | PTGDR2PTGDRALDH1A1 | |
| SCHEMBL1269665 | 0.84 | HTT (0.40) | ALDH1A1 | |
| SCHEMBL1268682 | 0.83 | KMT2A (0.43) | ALDH1A1 | |
| SCHEMBL1269586 | 0.81 | PIK3C3 (0.38) | PTGDR2PTGDRPPARGHSD11B1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | PTGDR2 649/4885PTGDR 709/4885RORC 39/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | PTGDR2 649/4885PTGDR 709/4885RORC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.